Top

Published in:

01-02-2017 | Original Scientific Report

Prognostic Relevance of the Timing of Initiating and the Completion of Adjuvant Therapy in Patients with Resected Pancreatic Ductal Adenocarcinoma

Authors: Woohyung Lee, Yoo-Seok Yoon, Ho-Seong Han, Jin Young Jang, Jai Young Cho, Woohyun Jung, Wooil Kwon, YoungRok Choi, Sun-Whe Kim

Published in: World Journal of Surgery | Issue 2/2017

Abstract

Background

Although the role of adjuvant therapy in patients with pancreatic ductal adenocarcinoma (PDAC) is well established, its optimal timing and duration are still controversial.

Methods

The study included 311 patients with PDAC who underwent curative resection followed by adjuvant therapy. We analyzed survival data according to the timing of initiation and completion of adjuvant therapy.

Results

There were no differences in 5-year overall survival (OS) (32.8 vs. 35.4%, p = 0.539) and disease-free survival (DFS) rates (26.2 vs. 23.3%, p = 0.865) between early (≤6 weeks) and late (>6 weeks) initiation of adjuvant therapy. However, the 5-year OS (42.6 vs. 22.2%, p < 0.001) and DFS (29.2 vs. 18.4%, p = 0.042) rates were significantly greater in patients with complete versus incomplete adjuvant therapy. Multivariable analysis revealed that incomplete adjuvant therapy was an independent prognostic factor for decreased OS (p = 0.001; hazard ratio 1.850; 95% confidence interval 1.266–2.702).

Conclusions

The results show that complete adjuvant therapy is a more important prognostic factor than early initiation for improving the survival of patients with resected PDAC.

Jemal A, Siegel R, Xu J et al (2010) Cancer statistics, 2010. CA Cancer J Clin 60:277–300CrossRefPubMed

Warshaw AL, Fernandez-del Castillo C (1992) Pancreatic carcinoma. N Engl J Med 326:455–465CrossRefPubMed

Wray CJ, Ahmad SA, Matthews JB et al (2005) Surgery for pancreatic cancer: recent controversies and current practice. Gastroenterology 128:1626–1641CrossRefPubMed

Shimoda M, Kubota K, Shimizu T et al (2015) Randomized clinical trial of adjuvant chemotherapy with S-1 versus gemcitabine after pancreatic cancer resection. Br J Surg 102:746–754CrossRefPubMed

Neoptolemos JP, Stocken DD, Bassi C et al (2010) Adjuvant chemotherapy with fluorouracil plus folinic acid versus gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA 304:1073–1081CrossRefPubMed

Neoptolemos JP, Stocken DD, Friess H et al (2004) A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 350:1200–1210CrossRefPubMed

Bayraktar S, Bayraktar UD, Rocha-Lima CM (2010) Timing of adjuvant and neoadjuvant therapy in colorectal cancers. Clin Colorectal Cancer 9:144–149CrossRefPubMed

Hershman D, Hall MJ, Wang X et al (2006) Timing of adjuvant chemotherapy initiation after surgery for stage III colon cancer. Cancer 107:2581–2588CrossRefPubMed

Chau I, Norman AR, Cunningham D et al (2005) A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer. Ann Oncol 16:549–557CrossRefPubMed

10.

Haeno H, Gonen M, Davis MB et al (2012) Computational modeling of pancreatic cancer reveals kinetics of metastasis suggesting optimum treatment strategies. Cell 148:362–375CrossRefPubMedPubMedCentral

11.

Valle JW, Palmer D, Jackson R et al (2014) Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study. J Clin Oncol 32:504–512CrossRefPubMed

12.

Murakami Y, Uemura K, Sudo T et al (2013) Early initiation of adjuvant chemotherapy improves survival of patients with pancreatic carcinoma after surgical resection. Cancer Chemother Pharmacol 71:419–429CrossRefPubMed

13.

U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute (2010) Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0. NIH publication 09-7473

14.

Regine WF, Winter KA, Abrams RA et al (2008) Fluorouracil versus gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. JAMA 299:1019–1026CrossRefPubMed

15.

Neoptolemos JP, Dunn JA, Stocken DD et al (2001) Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet 358:1576–1585CrossRefPubMed

16.

Ueno H, Kosuge T, Matsuyama Y et al (2009) A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer. Br J Cancer 101:908–915CrossRefPubMedPubMedCentral

17.

Wo JY, Childs SK, Szymonifka J et al (2014) Delaying chemoradiation until after completion of adjuvant chemotherapy for pancreatic cancer may not impact local control. Pract Radiat Oncol 4:e117–e123CrossRefPubMed

18.

Sharma C, Horowitz D, Chabot J et al (2011) Adjuvant therapy of pancreatic cancer. Highlights from the “2011 ASCO Annual Meeting”. Chicago, IL, USA; June 3–7, 2011. JOP 12:343–346PubMed

19.

Van Laethem JL, Verslype C, Iovanna JL et al (2012) New strategies and designs in pancreatic cancer research: consensus guidelines report from a European expert panel. Ann Oncol 23:570–576CrossRefPubMed

20.

Ryan DP, Hong TS, Bardeesy N (2014) Pancreatic adenocarcinoma. N Engl J Med 371:1039–1049CrossRefPubMed

21.

Park JW, Jang JY, Kim EJ et al (2013) Effects of pancreatectomy on nutritional state, pancreatic function and quality of life. Br J Surg 100:1064–1070CrossRefPubMed

22.

Akahori T, Sho M, Tanaka T et al (2016) Factors associated with failure to complete adjuvant chemotherapy in pancreatic cancer. Am J Surg 211:787–792CrossRefPubMed

23.

Liao WC, Chien KL, Lin YL et al (2013) Adjuvant treatments for resected pancreatic adenocarcinoma: a systematic review and network meta-analysis. Lancet Oncol 14:1095–1103CrossRefPubMed

Title: Prognostic Relevance of the Timing of Initiating and the Completion of Adjuvant Therapy in Patients with Resected Pancreatic Ductal Adenocarcinoma
Authors: Woohyung Lee
Yoo-Seok Yoon
Ho-Seong Han
Jin Young Jang
Jai Young Cho
Woohyun Jung
Wooil Kwon
YoungRok Choi
Sun-Whe Kim
Publication date: 01-02-2017
Publisher: Springer International Publishing
Published in: World Journal of Surgery / Issue 2/2017
Print ISSN: 0364-2313
Electronic ISSN: 1432-2323
DOI: https://doi.org/10.1007/s00268-016-3798-1

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Prognostic Relevance of the Timing of Initiating and the Completion of Adjuvant Therapy in Patients with Resected Pancreatic Ductal Adenocarcinoma

Abstract

Background

Methods

Results

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2017

The Impact of Healthcare Privatization on Access to Surgical Care: Cholecystectomy as a Model

Handcrafted Vacuum-Assisted Device for Skin Ulcers Treatment Versus Traditional Therapy, Randomized Controlled Trial

Improvement of Postoperative Pain Control Processes and Outcomes in Veterans of a Surgical Intensive Care Unit

Outcome of Laparoscopic Treatment of Anorectal Malformations in Children

Erratum to: Prognostic Relevance of the Timing of Initiating and the Completion of Adjuvant Therapy in Patients with Resected Pancreatic Ductal Adenocarcinoma

Surgical Strategy and Outcome in Patients Undergoing Pancreaticoduodenectomy After Gastric Resection: A Three-Center Experience with 39 Patients